Q2 2026 · Form 13F LedgerData source: SEC EDGAR  
H

HOLDER.TOP

Who owns what — the quarterly ledger of U.S. institutional holdings.
EN · 简 · 繁
Funds / TCG Crossover Management, LLC
Form 13F · Q2 2026

TCG Crossover Management, LLC

CIK 1839948Filed 2026-08-1413F-HR View the filing on EDGAR ↗
$4.2B
Reported book value
54
Positions
12
Quarters on record
Top 50
Positions

TCG Crossover Management, LLC — holdings

Top 50 positions of 54, ranked by reported value. Share change is versus the previous quarter.
#SecuritySharesShare Δ QoQValue% of book
1ABIVAX SA Abivax Sa6.0M−7.3%$801M19.2%
2TNGX Tango Therapeutics Inc9.1M−13.8%$284M6.8%
3CGON Cg Oncology Inc3.7M+0.0%$261M6.3%
4COGT Cogent Biosciences Inc4.9M−1.9%$188M4.5%
5IMVT Immunovant Inc4.5M+0.0%$172M4.1%
6SYRE Spyre Therapeutics Inc1.9M+0.0%$169M4.1%
7DNTH Dianthus Therapeutics Inc1.7M+0.0%$163M3.9%
8MIRM Mirum Pharmaceuticals Inc1.1M+0.0%$124M3.0%
9ZLAB Zai Lab Ltd6.1M—$117M2.8%
10AMLX Amylyx Pharmaceuticals Inc6.2M+0.0%$112M2.7%
11GLUE Monte Rosa Therapeutics Inc4.6M+0.0%$112M2.7%
12BCRX Biocryst Pharmaceuticals Inc11.0M+0.0%$110M2.6%
13VOR Vor Biopharma Inc5.7M+0.0%$104M2.5%
14TYRA Tyra Biosciences Inc3.2M+0.0%$104M2.5%
15DYN Dyne Therapeutics Inc4.6M+0.0%$103M2.5%
16IRON Disc Medicine Inc1.3M+0.0%$98M2.4%
17RLAY Relay Therapeutics Inc4.3M+0.0%$80M1.9%
18SVRA Savara Inc12.4M+0.0%$76M1.8%
19AURA Aura Biosciences Inc9.5M—$68M1.6%
20RVMD Revolution Medicines Inc340,899−40.9%$64M1.5%
21TRAX First Tracks Biotherapeutics2.9M—$58M1.4%
22KOD Kodiak Sciences Inc1.4M+0.0%$56M1.4%
23AVTX Avalo Therapeutics Inc3.0M+308.6%$56M1.3%
24LBRX Lb Pharmaceuticals Inc1.4M−21.3%$47M1.1%
25IPSC Century Therapeutics Inc17.8M+0.0%$43M1.0%
26TECX Tectonic Therapeutic Inc1.2M+0.0%$41M1.0%
27XNCR Xencor Inc2.5M+0.0%$39M0.9%
28SRZN Surrozen Inc1.5M+0.0%$38M0.9%
29EDIT Editas Medicine Inc11.1M—$36M0.9%
30MBX Mbx Biosciences Inc650,000+0.0%$36M0.9%
31PHVS Pharvaris N V1.0M—$35M0.8%
32SLN Silence Therapeutics Plc3.0M+0.0%$33M0.8%
33INFLARX NV Inflarx Nv14.5M—$32M0.8%
34ALT Altimmune Inc10.0M—$30M0.7%
35JANX Janux Therapeutics Inc1.8M+0.0%$27M0.7%
36CATX Perspective Therapeutics Inc7.9M+0.0%$27M0.6%
37AGMB Agomab Therapeutics Nv2.1M+0.0%$27M0.6%
38BHVN Biohaven Ltd1.8M−61.6%$26M0.6%
39AKTS Aktis Oncology Inc696,560—$22M0.5%
40ALEC Alector Inc10.0M+0.0%$20M0.5%
41FORTE BIOSCIENCES INC Forte Biosciences Inc920,000—$20M0.5%
42MNPR Monopar Therapeutics Inc203,327+53.9%$19M0.5%
43OCUL Ocular Therapeutix Inc1.6M+0.0%$16M0.4%
44ADCT Adc Therapeutics Sa11.4M+0.0%$12M0.3%
45ALXO Alx Oncology Hldgs Inc5.7M−56.5%$12M0.3%
46TRDA Entrada Therapeutics Inc1.1M−53.7%$8M0.2%
47CGEM Cullinan Therapeutics Inc406,786+0.0%$7M0.2%
48ARVN Arvinas Inc707,098−70.4%$6M0.1%
49KRRO Korro Bio Inc416,301+0.0%$5M0.1%
50RACC Research Alliance Corp Iii500,000—$5M0.1%
Source: Form 13F filings via SEC EDGAR. Positions as of Jun 30, 2026. Options (put/call) are excluded from share counts.